
Plaque volume begins to regress once LDL-C falls below about 90 mg/dL across RCTs
Louis explains a JACC chart that plots LDL-C against change in total atheroma volume across the major plaque-regression trials of statins, PCSK9 inhibitors, ezetimibe and other drugs. Reversal of total plaque volume begins around LDL-C below about 90 mg/dL, and the best statin result was in Japan-ACS.




